Leerink Raises AbbVie (ABBV) Price Target on Strong Business Performance

Core Insights - AbbVie Inc. (NYSE:ABBV) is recognized for its low beta stocks that can outperform market volatility, with Leerink Partners maintaining an Outperform rating and raising the price target from $210 to $243 following a settlement allowing generic Rinvoq introduction in April 2037 [1][2] Group 1: Business Performance - AbbVie is experiencing "very strong current business performance," particularly with the ongoing expansion of Skyrizi despite its substantial market dominance [2] - The firm anticipates that as pressure from Humira biosimilars decreases, AbbVie's total top-line growth will accelerate from 8% in 2025 to 11% in 2026 [3] Group 2: Product Pipeline - AbbVie specializes in developing therapies for complex and chronic illnesses, with Rinvoq and Skyrizi being key drivers of growth [4] - Leerink has identified three oncology pipeline candidates that are expected to significantly contribute to AbbVie's revenue in the future [3]